AR057976A1 - SUBSTITUTED BIARILOS AND ITS USE AS MEDICINES. - Google Patents

SUBSTITUTED BIARILOS AND ITS USE AS MEDICINES.

Info

Publication number
AR057976A1
AR057976A1 ARP060103699A ARP060103699A AR057976A1 AR 057976 A1 AR057976 A1 AR 057976A1 AR P060103699 A ARP060103699 A AR P060103699A AR P060103699 A ARP060103699 A AR P060103699A AR 057976 A1 AR057976 A1 AR 057976A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
atom
substituted
independently
Prior art date
Application number
ARP060103699A
Other languages
Spanish (es)
Inventor
Annette Schuler-Metz
Herbert Nar
Georg Dahmann
Kai Gerlach
Roland Pfau
Henning Priepke
Wolfgang Wienen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35559394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057976(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR057976A1 publication Critical patent/AR057976A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Biarilos sustituidos y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Compuestos de la formula general (1), en la que A es un radical del grupo de formulas (2); X1 es un grupo carbonilo, tiocarbonilo, -C(N-R4c)-, -C(NOR4c)-, -C(N- NO2)-, -C(NCN)- o sulfonilo; X2 es un átomo de oxígeno o un grupo -N(R4b)-; X3 es un átomo de oxigeno o de azufre o un grupo -N(R4c)-; m es el numero 1 o 2; L es un grupo heteroarileno monocíclico de 5 miembros sustituido eventualmente en la estructura del carbono con un grupo R5a y las dos uniones mostradas en la formula (1) pueden producirse a través de dos átomos de carbono o un grupo imino y un átomo de carbono del heterociclo, en donde un grupo -NH- eventualmente existente puede estar reemplazado por un grupo -N(R5b)-; B es un radical de la formula general -G-T; G es un resto seleccionado del grupo de formulas (3); T es un grupo heteroarilo o fenilo monocíclico de 5 o 6 miembros, que está eventualmente sustituido en uno o dos átomos de carbono de modo independiente entre sí con R6; R1 es un átomo de hidrogeno, fluor, cloro, bromo o yodo, un grupo alquilo C1-3 o alcoxi C1-3, en donde los átomos de hidrogeno del grupo alquilo C1-3 o alcoxi C1-3 pueden estar eventualmente total o parcialmente reemplazados por átomos de fluor, un grupo alquenilo C2-3, alquinilo C2-3, nitrilo, nitro o amino; R2 es un átomo de hidrogeno o de halogeno o un grupo alquilo C1-3 o alcoxi C1-3, en donde los átomos de hidrogeno del grupo alquilo C1-3 o alcoxi C1-3 pueden estar reemplazados eventualmente total o parcialmente por átomos de fluor; R3a y R3b son cada uno, de modo independiente entre sí, un átomo de hidrogeno, un grupo alquenilo C2-5 o alquinilo C2-5, un grupo alquilo C1-5 de cadena lineal o ramificada, en donde los átomos de hidrogeno del grupo alquilo C1-5 de cadena lineal o ramificada pueden estar reemplazados, en su totalidad o en parte, por átomos de fluor, y que puede estar eventualmente sustituido con un grupo R7a, R7b, R7c o un grupo alquiloxi C1-4 que está sustituido con un grupo R7b, un mercapto, un grupo alquilsulfanilo C1-5, alquilsulfonilo C1-5, un grupo R7b o R7c, un grupo cicloalquilo de 3 a 7 miembros, cicloalquil-alquilo C1-5 o cicloalquilenimino-alquilo C1-3, en donde en el caso de los ciclos de 4 a 7 miembros en la parte cíclica, un grupo metilo puede estar eventualmente reemplazado por un grupo -N(R4c)-, un átomo de oxígeno o de azufre o un grupo carbonilo, -S(O)- o - S(O)2-, o en donde en el caso de ciclos de 4 a 7 miembros en la parte cíclica, dos grupos metileno adyacentes juntos pueden estar eventualmente reemplazados por un grupo -C(O)N(R4b)- o -S(O)2N(R4b)-, en donde un grupo cicloalquilo de 3 a 7 miembros, cicloalquilenimino, cicloalquil-alquilo C1-5 o cicloalquilenimino-alquilo C1-3 en uno o dos grupos -CH2- puede estar sustituido con uno o dos grupos R4a, con la condicion de que esté excluido un grupo cicloalquilo, cicloalquilenimino, cicloalquil- alquilo C1-5 o cicloalquilenimino-alquilo C1-3 de 3 a 7 miembros, definido como arriba, en el que dos heteroátomos del grupo oxígeno y nitrogeno están separados entre sí por exactamente un grupo -CH2- eventualmente sustituido, o R3a y R3b forman junto con el átomo de carbono al que están unidos, un grupo cicloalquilo C3-8 o cicloalquenilo C3-8, en donde un grupo cicloalquilo C3-8 en un unico átomo de carbono puede estar sustituido con un grupo alquileno C2-5 o al mismo tiempo en dos átomos de carbono diferentes con un grupo alquileno C1-4 con la formacion de un espirociclo correspondiente o un biciclo en puente, en donde uno de los grupos metileno de un grupo cicloalquilo C4-8 o cicloalquenilo C5-8 o bien uno de los espirociclos o biciclos en puente correspondientes tal como se describieron con anterioridad puede estar reemplazado por un átomo de oxígeno o de azufre o un grupo -B(R4c)-, o un grupo carbonilo, sulfinilo o sulfonilo, y/o dos grupos metileno directamente adyacentes de un grupo cicloalquilo C4-8 pueden estar reemplazados por un grupo -C(O)N(R4b)-, -C(O)O- o -S(O)2N(R4b)-, y/o tres grupos metileno directamente adyacentes de un grupo cicloalquilo C6-8 juntos pueden estar reemplazados por un grupo - OC(O)N(R4b)-, -N(R4b)C(O)N(R4b)- o -N(R4b)S(O)2N(R4b)-, en donde 1 a 3 átomos de carbono de un grupo cicloalquilo C3-8 o bien uno de los espirociclos o biciclos en puente correspondientes tal como se describieron con anterioridad pueden estar eventualmente sustituidos, de modo independiente entre sí, con uno o dos átomos de fluor o uno o dos grupos alquilo iguales o diferentes o grupos R7a o R7b o carboxialquilo C1-5, alquil C1-5-oxicarbonil-alquilo C1-5, alquil C1-5-sulfanilo o alquil C1-5-sulfonilo, en donde 1 a 2 átomos de carbono de un grupo cicloalquenilo C3-8 pueden estar eventualmente sustituidos, de modo independiente entre sí, con un grupo alquilo C1-5 o un grupo R7b, y 1 a 2 átomos de carbono sp3-hibridados de un grupo cicloalquenilo C4-8 pueden estar eventualmente sustituidos, de modo independiente entre sí, con uno o dos átomos de fluor o un grupo R7b, con la condicion de que un grupo cicloalquilo C3-8 o cicloalquenilo C3-8 formado por R3a y R3b juntos o bien un espirociclo correspondiente descrito como con anterioridad o un biciclo en puente correspondiente, en el que dos heteroátomos en el ciclo del grupo oxígeno y nitrogeno están separados uno de otro exactamente por un grupo -CH2 eventualmente sustituido, y/o en donde uno o ambos grupos metileno del ciclo, que están directamente unidos con el átomo de carbono, están unidos con los radicales R3a y R3b, están reemplazados por un heteroátomo del grupo oxígeno, nitrogeno y azufre, y/o en el que un sustituyente unido al grupo cíclico, el cual se caracteriza porque un heteroátomo del grupo átomo de oxígeno, nitrogeno, azufre y halogeno está unido directamente al grupo cíclico, está separado, mediante exactamente un grupo metileno, eventualmente sustituido, de otro heteroátomo del grupo oxígeno, nitrogeno y azufre, con excepcion del grupo sulfona, y/o en donde dos átomos de oxígeno están directamente unidos entre sí, y/o en donde un heteroátomo del grupo oxígeno, nitrogeno y azufre están unidos directamente con el átomo de carbono, que está unido con otro átomo de carbono a través de un enlace doble, y/o que contiene un ciclo con tres miembros de anillo, de los cuales uno o varios corresponden al grupo de átomo de oxígeno o de azufre o -N(R4c)-; R4a son, de modo independiente entre sí, un átomo de hidrogeno o de fluor o un grupo alquilo C1-4 eventualmente sustituido con un grupo R7a, R7b o R7c o que representa como sustituyente de un átomo de carbono sp3- hibridado un grupo R7a, R7b, o R7c, en donde en el caso de los radicales A de 5 a 7 miembros sustituidos mencionados con anterioridad, los heteroátomos F, O o N eventualmente introducidos con como sustituyentes no están separados justamente por un átomo de carbono sp3-hibridado de un heteroátomo del grupo N, O, S; R4b son cada uno, de modo independiente entre sí, un átomo de hidrogeno o un grupo alquilo C1-5; R4c son cada uno, de modo independiente entre sí, un átomo de hidrogeno, un grupo alquilo C1-5, alquil C1-5-carbonilo, alquil C1-5-oxicarbonilo o alquil C1-5-sulfonilo; R5a son cada uno, de modo independiente entre sí, un átomo de hidrogeno o de halogeno o un grupo alquilo C1-4 eventualmente sustituido con un grupo R7a, R7b, R7c o R7e, en donde los átomos de hidrogeno están total o parcialmente reemplazados por átomos de fluor, o un grupo R7a, R7b, R7c o R7e, en donde cada grupo R7c en la estructura de carbono puede estar sustituido con uno o dos grupos seleccionados de átomo de halogeno, grupo alquilo C1-4 y grupos R7a, R7b y R7e así como en el caso de heterociclos de 5 miembros en un átomo de nitrogeno sustituible puede estar sustituido con un grupo alquilo C1-4 eventualmente sustituido con R7a, en donde un heteroátomo introducido con R7a como sustituyente del grupo alquilo está separado del átomo de nitrogeno del heterociclo por al menos dos grupos metileno, o con R7a, y el grupo R7b o R7e en la estructura de carbono puede estar sustituidos con uno o dos grupos alquilo C1-4, que a su vez pueden estar sustituidos de modo independiente entre sí con un grupo R7a; R5b son cada uno, de modo independiente entre sí, un átomo de hidrogeno o un grupo alquilo C1-5 eventualmente sustituido con un grupo R7a, R7b, R7c o R7e o un grupo R7a, R7c o R7e, en donde el grupo R7c en la estructura de carbono puede estar sustituida con uno o dos grupos seleccionados de átomo de halogeno, grupo alquilo C1-4 , y grupos R7a, R7b y R7e así como en el caso de heterociclos de 5 miembros en un átomo de nitrogeno sustituible, con un grupo alquilo C1-4 eventualmente sustituido con R7a, en donde un heteroátomo introducido con R7a como sustituyente del grupo alquilo está separado del átomo de nitrogeno del heterociclo por al menos dos grupos metileno, o con R7a, y el grupo R7e en la estructura de carbono puede estar sustituido con uno o dos grupos alquilo C1-4, que a su vez puede estar sustituido de modo independiente entre sí con un grupo R7a, en donde los heteroátomos introducidos eventualmente con R7a como sustituyente, O o N no están separados justamente con átomo de carbono del átomo de nitrogeno sustituido con R5b en el heterociclo; R6 es un átomo de fluor, cloro, bromo o yodo, un grupo nitro, amino, nitrilo, hidroxi, alquenilo C2-3, alquinilo C2-3, alquilo C1-3 o un grupo alcoxi C1-3, en donde los átomos de hidrogeno del grupo alquilo C1-3 o alcoxi C1-3 pueden estar eventualmente total o parcialmente reemplazados por átomos de fluor; R7a son cada uno, de modo independiente entre sí, un grupo hidroxilo o un grupo R7d; R7b son cada uno, de modo independiente entre sí, un grupo carboxi, alcoxi C1-3-carbonilo, aminocarbonilo, alquil C1-3-aminocarbonilo, di-(alquil C1-3)- aminocarbonilo, morfolin-4-iI-carbonilo, (4-alquil C1-3-piperazin-1-il)-carbonilo, (4-[alquil C1-3)-carbonil]-piperazin-1-il)-carbonilo, un grupoSubstituted biaryls and pharmaceutical compositions comprising them. Claim 1: Compounds of the general formula (1), wherein A is a radical of the group of formulas (2); X1 is a carbonyl, thiocarbonyl, -C (N-R4c) -, -C (NOR4c) -, -C (N-NO2) -, -C (NCN) - or sulfonyl group; X2 is an oxygen atom or a group -N (R4b) -; X3 is an oxygen or sulfur atom or a group -N (R4c) -; m is the number 1 or 2; L is a 5-membered monocyclic heteroarylene group optionally substituted in the carbon structure with an R5a group and the two bonds shown in formula (1) can be produced through two carbon atoms or an imino group and a carbon atom of the heterocycle, where an optionally -NH- group may be replaced by a group -N (R5b) -; B is a radical of the general formula -G-T; G is a remainder selected from the group of formulas (3); T is a 5 or 6 membered monocyclic heteroaryl or phenyl group, which is optionally substituted on one or two carbon atoms independently of each other with R6; R1 is a hydrogen, fluorine, chlorine, bromine or iodine atom, a C1-3 alkyl or C1-3 alkoxy group, wherein the hydrogen atoms of the C1-3 alkyl or C1-3 alkoxy group may eventually be wholly or partially replaced by fluorine atoms, a C2-3 alkenyl group, C2-3 alkynyl, nitrile, nitro or amino; R2 is a hydrogen or halogen atom or a C1-3alkyl or C1-3alkoxy group, wherein the hydrogen atoms of the C1-3alkyl or C1-3alkoxy group may optionally or partially be replaced by fluorine atoms ; R3a and R3b are each, independently of each other, a hydrogen atom, a C2-5 alkenyl or C2-5 alkynyl group, a straight or branched C1-5 alkyl group, wherein the hydrogen atoms of the group C1-5 straight or branched chain alkyl may be replaced, in whole or in part, by fluorine atoms, and which may eventually be substituted with a group R7a, R7b, R7c or a C1-4 alkyloxy group which is substituted with an R7b group, a mercapto, a C1-5 alkylsulfanyl group, C1-5 alkylsulfonyl group, an R7b or R7c group, a 3 to 7 membered cycloalkyl group, cycloalkyl-C1-5 alkyl or cycloalkyleneimino-C1-3 alkyl, wherein in the case of the 4 to 7 member cycles in the cyclic part, a methyl group may eventually be replaced by a group -N (R4c) -, an oxygen or sulfur atom or a carbonyl group, -S (O) - or - S (O) 2-, or where in the case of cycles of 4 to 7 members in the cyclic part, two adjacent methylene groups together pu They may eventually be replaced by a group -C (O) N (R4b) - or -S (O) 2N (R4b) -, where a 3- to 7-membered cycloalkyl group, cycloalkyleneimino, cycloalkyl-C1-5 alkyl or cycloalkyleneimino -C1-3 alkyl in one or two groups -CH2- may be substituted with one or two R4a groups, with the proviso that a cycloalkyl, cycloalkyleneimino, cycloalkyl-C1-5 alkyl or cycloalkyleneimino-C1-3 alkyl group is excluded 3 to 7 members, defined as above, in which two heteroatoms of the oxygen and nitrogen group are separated from each other by exactly one optionally substituted -CH2- group, or R3a and R3b form together with the carbon atom to which they are attached, a C3-8 cycloalkyl or C3-8 cycloalkenyl group, wherein a C3-8 cycloalkyl group in a single carbon atom may be substituted with a C2-5 alkylene group or at the same time in two different carbon atoms with a C1 alkylene group -4 with the formation of a corresponding spirocycle or a bicycle in bridge, wherein one of the methylene groups of a C4-8 cycloalkyl or C5-8 cycloalkenyl group or one of the corresponding spirocycles or bridge bicycles as described above may be replaced by an oxygen or sulfur atom or a group -B (R4c) -, or a carbonyl, sulfinyl or sulfonyl group, and / or two directly adjacent methylene groups of a C4-8 cycloalkyl group may be replaced by a group -C (O) N (R4b) -, -C (O) O- or -S (O) 2N (R4b) -, and / or three directly adjacent methylene groups of a C6-8 cycloalkyl group together may be replaced by a group - OC (O) N (R4b) -, -N (R4b) C (O) N (R4b) - or -N (R4b) S (O) 2N (R4b) -, wherein 1 to 3 carbon atoms of a C3-8 cycloalkyl group or one of the corresponding spirocycles or bridge bicycles as described above may eventually be substituted, independently of one another, with one or two fluorine atoms or one or two equal or different alkyl groups or R7a or R7b groups or C1-5 carboxyalkyl, C1-5 alkyl-oxycarbonyl-C1-5 alkyl, C1-5 alkyl sulfanyl or C1-5 alkyl sulfonyl, wherein 1 to 2 carbon atoms of a C3 cycloalkenyl group -8 may optionally be substituted, independently of one another, with a C1-5 alkyl group or an R7b group, and 1 to 2 sp3-hybridized carbon atoms of a C4-8 cycloalkenyl group may eventually be substituted, independently each other, with one or two fluorine atoms or an R7b group, with the proviso that a C3-8 cycloalkyl or C3-8 cycloalkenyl group formed by R3a and R3b together or a corresponding spirocycle described as above or a bicyclo in corresponding bridge, in which two heteroatoms in the oxygen and nitrogen group cycle are separated from each other exactly by an optionally substituted -CH2 group, and / or where one or both methylene groups of the cycle, which are directly linked to the atom of carbon, are linked with radicals R3a and R3b, are replaced by a heteroatom of the oxygen, nitrogen and sulfur group, and / or in which a substituent attached to the cyclic group, which is characterized in that a hetero atom of the oxygen, nitrogen, sulfur and halogen atom group is directly linked to the cyclic group, it is separated, by exactly one methylene group, optionally substituted, from another heteroatom of the oxygen, nitrogen and sulfur group, with the exception of the sulfone group, and / or where two oxygen atoms are directly linked to each other, and / or wherein a heteroatom of the oxygen, nitrogen and sulfur group are directly linked to the carbon atom, which is linked to another carbon atom through a double bond, and / or that contains a cycle with three ring members , of which one or more correspond to the group of oxygen or sulfur atom or -N (R4c) -; R4a are, independently of each other, a hydrogen or fluorine atom or a C1-4 alkyl group optionally substituted with a group R7a, R7b or R7c or representing as a substituent of a sp3-hybridized carbon atom a group R7a, R7b, or R7c, where in the case of the above-mentioned substituted 5- to 7-membered radicals A, the F, O or N heteroatoms possibly introduced with as substituents are not just separated by a sp3-hybridized carbon atom from a heteroatom of group N, O, S; R4b are each, independently of each other, a hydrogen atom or a C1-5 alkyl group; R4c are each, independently of each other, a hydrogen atom, a C1-5 alkyl, C1-5 alkylcarbonyl, C1-5 alkylcarboxylic or C1-5 alkyl sulfonyl group; R5a are each, independently of each other, a hydrogen or halogen atom or a C1-4 alkyl group optionally substituted with a group R7a, R7b, R7c or R7e, where the hydrogen atoms are totally or partially replaced by fluorine atoms, or a group R7a, R7b, R7c or R7e, wherein each group R7c in the carbon structure may be substituted with one or two groups selected from halogen atom, C1-4 alkyl group and groups R7a, R7b and R7e as well as in the case of 5-membered heterocycles in a substitutable nitrogen atom may be substituted with a C1-4 alkyl group optionally substituted with R7a, wherein a heteroatom introduced with R7a as a substituent of the alkyl group is separated from the nitrogen atom of the heterocycle by at least two methylene groups, or with R7a, and the group R7b or R7e in the carbon structure may be substituted with one or two C1-4 alkyl groups, which in turn may be independently substituted ent yes with an R7a group; R5b are each, independently of each other, a hydrogen atom or a C1-5 alkyl group optionally substituted with a group R7a, R7b, R7c or R7e or a group R7a, R7c or R7e, wherein the group R7c in the Carbon structure may be substituted with one or two groups selected from halogen atom, C1-4 alkyl group, and R7a, R7b and R7e groups as well as in the case of 5-membered heterocycles in a substitutable nitrogen atom, with a group C1-4 alkyl optionally substituted with R7a, wherein a heteroatom introduced with R7a as a substituent of the alkyl group is separated from the nitrogen atom of the heterocycle by at least two methylene groups, or with R7a, and the group R7e in the carbon structure can be substituted with one or two C1-4 alkyl groups, which in turn can be independently substituted with each other with a group R7a, wherein the heteroatoms possibly introduced with R7a as a substituent, O or N are not just separated with volume carbon atom substituted with R5b nitrogen in the heterocycle; R6 is a fluorine, chlorine, bromine or iodine atom, a nitro, amino, nitrile, hydroxy, C2-3 alkenyl, C2-3 alkynyl, C1-3 alkyl or a C1-3 alkoxy group group, wherein the atoms of hydrogen of the C1-3 alkyl or C1-3 alkoxy group may optionally be totally or partially replaced by fluorine atoms; R7a are each, independently of each other, a hydroxyl group or an R7d group; R7b are each, independently of each other, a carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-aminocarbonyl, di- (C1-3 alkyl) -aminocarbonyl, morpholin-4-i-carbonyl group, (4-C1-3 alkyl-piperazin-1-yl) -carbonyl, (4- [C1-3 alkyl) -carbonyl] -piperazin-1-yl) -carbonyl, a group

ARP060103699A 2005-08-29 2006-08-25 SUBSTITUTED BIARILOS AND ITS USE AS MEDICINES. AR057976A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107891 2005-08-29

Publications (1)

Publication Number Publication Date
AR057976A1 true AR057976A1 (en) 2008-01-09

Family

ID=35559394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103699A AR057976A1 (en) 2005-08-29 2006-08-25 SUBSTITUTED BIARILOS AND ITS USE AS MEDICINES.

Country Status (3)

Country Link
AR (1) AR057976A1 (en)
TW (1) TW200738693A (en)
WO (1) WO2007025940A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002099A2 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007131179A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
SG174087A1 (en) * 2006-08-21 2011-09-29 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
DE102007028319A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
JP5524852B2 (en) 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted amides, their production and use as pharmaceuticals
WO2009063029A2 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
WO2009102761A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP2140866A1 (en) * 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CN111116483B (en) * 2019-11-25 2022-12-20 浙江师范大学 2-imidazolyl imidazole compound and preparation method thereof
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725244D0 (en) * 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10254336A1 (en) * 2002-11-21 2004-06-03 Merck Patent Gmbh carboxamides

Also Published As

Publication number Publication date
TW200738693A (en) 2007-10-16
WO2007025940A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
AR057976A1 (en) SUBSTITUTED BIARILOS AND ITS USE AS MEDICINES.
AR078152A1 (en) HETEROCICLICAL COMPOUNDS, USEFUL FOR THE TREATMENT OF HCV AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
AR048641A1 (en) ARTH- OR HETEROARILAMIDE ORTHOSUSTITUTED COMPOUNDS USEFUL AS ANTAGO-NISTAS OF THE PROSTAGLANDINAS E2 RECEIVER; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICAME
AR032752A1 (en) UREIDO PROPIONAMIDS OR PROPIONAMIDS TRANS-HEREROAROMATIC 2,3-DI-SUBSTITUTES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL AS GLUCO ACTIVATORS
CO6480980A2 (en) PHARMACEUTICAL COMPOSITION FOR A PROTEASE INHIBITOR OF HEPATITIS C VIRUS
AR030053A1 (en) 1H-PIRIMIDO [4,5-D] PIRIMIDIN-2-ONAS AND SALTS, PHARMACEUTICAL COMPOSITIONS, USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR PRODUCERS
AR038377A1 (en) DERIVATIVES OF N-BIFENIL-AMINOCICLOALCANCARBOXAMIDA (WITH REPLACEMENT WITH METHYL)
AR054871A1 (en) DERIVATIVES OF (HETERO) CICLOALQUILETINIL-BENCIL) -BENZENE REPLACED WITH GLUCOPIRANOSIL, MEDICINES CONTAINING SUCH COMPOUNDS, ITS USE AND PROCESS FOR MANUFACTURING
AR048282A1 (en) INDOL- O - SUBSTITUTED GLUCOSIDS
PE20050123A1 (en) DERIVATIVES OF BENZOCONDENSATED HETEROARYLAMIDE OF HAENOPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
CO6251270A2 (en) NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL ITS PREPARATION PROCEDURE ITS APPLICATION AS MEDICINES PHARMACEUTICAL COMPOSITIONS AND NEW USE MAINLY AS MET INHIBITORS
AR056347A1 (en) USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
CO5680403A2 (en) MCHR1R ANTAGONISTS
PE20090042A1 (en) CYCLOPAMINE ANALOGS
PE20081798A1 (en) PIPERIDINE DERIVATIVES AND METHODS OF USE OF THE SAME
CO5640087A2 (en) COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY PHARMACOS DECONGESTIONANTES AND ANTI-HISTAMINIC
AR054524A1 (en) METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF CARBAMATE COMPOUNDS
AR054783A1 (en) PIRROLO-QUINOLINAS DERIVATIVES SELECTIVE MODULATORS OF ANDROGEN RECEPTORS
AR039256A1 (en) DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS
AR051797A1 (en) HYDANTOIN DERIVATIVES METALOPROTEINASE INHIBITORS
CO5560555A2 (en) HYDROXINOREFEDRINE DERIVATIVE CRYSTALS
SV2009003348A (en) NEW TRICYCLE DERIVATIVES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
NI201000134A (en) NEW DIHYDROINDOLONE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR054132A1 (en) DERIVATIVES OF AZOLOPIRIDIN-2-ONA AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
AR073089A1 (en) DERIVATIVES OF (POLI) AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA OR ALQUILSULFONAMIDA OF EPIPODOFILOTOXINA, A PROCESS TO PREPARE THEM, ITS APPLICATION IN THERAPY AS ANTICANCER AGENTS AND PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal